Ablynx NV (ABLX) - Financial and Strategic SWOT Analysis Review 5/3/2013 \| published by: GlobalData ... novel class of antibody-derived therapeutic proteins based on antibody fragments consisting of a single monomeric variable antibody domain. It has advantages of conventional antibodies along with the key features of small molecule drugs. Ablynx product ... \| read more...	$125.00
MediGene AG (MDG) - Financial and Strategic SWOT Analysis Review 5/3/2013 \| published by: GlobalData ... drugs, namely, Eligard, used for the treatment of hormone-dependent prostate cancer and Veregen, an ointment used to treat external genital warts. MediGene AG Key Recent Developments Mar 22, 2013: MediGene Reports Revenue Of €6m In ... \| read more...	$125.00
Daxor Corporation (DXR) - Financial and Strategic SWOT Analysis Review 5/3/2013 \| published by: GlobalData ... with Volumex , a single-use radiopharmaceutical diagnostic injection and collection kit. The company also offers cryobanking services including semen banking, autologous blood banking services, andrology services and general clinical laboratory testing through its subsidiary Scientific ... \| read more...	$125.00
Pain Therapeutics, Inc. (PTIE) - Financial and Strategic SWOT Analysis Review 5/3/2013 \| published by: GlobalData ... and three other abuse-resistant opioid product candidates, namely, hydromorphone, hydrocodone and oxymorphone. Pain Therapeutics entered into an alliance with Pfizer, Inc, to develop and commercialize Remoxy and Durect corporation for the use of its patented ... \| read more...	$125.00
Nanotechnology Market Outlook 2017 5/1/2013 \| published by: RNCOS ... number of industrial segments, and the economic activity generated from it has been high in magnitude and wide in scope. The nanotechnology-based products, which have had a huge impact on almost each industrial sector, are ... \| read more...	$1,500.00
Monoclonal Antibody Markets in China 5/1/2013 \| published by: Asia Market Information & Development Company ... investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers in ... \| read more...	$2,000.00
Global Seeds Market Report: 2013 Edition 5/1/2013 \| published by: Koncept Analytics ... the back of these advancements in the field of seed/plant biotechnology, incorporation of desired traits into the seeds has become possible. The very fact laid the foundation of hybrid seeds or genetically engineered/modified (GM) seeds. ... \| read more...	$800.00
US Personalized Cancer Genome Sequencing Marketrncos 5/1/2013 \| published by: RNCOS ... the most attractive sectors due to its inherent capability of high revenue generation and efficiency in terms of personalized treatment. In order to properly analyze the virtues and significance of the US personalized cancer Whole-Genome ... \| read more...	$1,200.00
Personalized Medicine Market Analysis 5/1/2013 \| published by: RNCOS ... per individuals. The growing research applications and identification of molecular markers towards disease predisposition and progression have led to the growth of personalized medicine. Industry players have also rapidly adopted this field and are progressing ... \| read more...	$1,200.00
Genetic Testing Market Outlook to 2017 5/1/2013 \| published by: RNCOS ... 140-page report. On account of our analysis of the past and present market trends; drivers; and existing strengths and challenges; forecast for genetic testing has been drawn, according to which, the market is likely to ... \| read more...	$1,200.00
PharmaSphere: Early-Stage Technology Transfer Collaborations - Enabling Platform Technologies & Deal Synergies between Academia and the Pharmaceutical Industry 4/30/2013 \| published by: GlobalData ... the Pharmaceutical Industry report provides a cross-section of major licensing deals between mid to large-sized pharmaceutical companies and academic and nonprofit research institutions. This report examines the terms, platform technologies, and deal rationale of 25 ... \| read more...	$2,995.00
Generex Biotechnology Corporation – Product Pipeline Review – 2013 4/30/2013 \| published by: Global Markets Direct ... focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Markets Direct’s proprietary databases, ... \| read more...	$1,500.00
Novartis AG – Product Pipeline Review – 2013 4/30/2013 \| published by: Global Markets Direct ... includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Novartis AG’s corporate ... \| read more...	$1,500.00
MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - EU Analysis and Market Forecasts 4/30/2013 \| published by: GlobalData ... market remains of high interest due to advancements in assay sensitivity both on laboratory and point-of-care platforms. GlobalData expects these advancements to have an impact on other diagnostic tests such as creatine kinase-MB isoenzyme and ... \| read more...	$4,450.00
MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 4/30/2013 \| published by: GlobalData ... of high interest due to advancements in assay sensitivity both on laboratory and point-of-care platforms. GlobalData expects these advancements to have an impact on other diagnostic tests such as creatine kinase-MB isoenzyme and myoglobin. Furthermore, ... \| read more...	$4,450.00
MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - US Analysis and Market Forecasts 4/30/2013 \| published by: GlobalData ... this market remains of high interest due to advancements in assay sensitivity both on laboratory and point-of-care platforms. GlobalData expects these advancements to have an impact on other diagnostic tests such as creatine kinase-MB isoenzyme ... \| read more...	$4,450.00
Genentech, Inc. – Product Pipeline Review – 2013 4/30/2013 \| published by: Global Markets Direct ... includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Genentech, Inc.’s corporate ... \| read more...	$1,500.00
MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - South America Analysis and Market Forecasts 4/30/2013 \| published by: GlobalData ... diagnostics market remains of high interest due to advancements in assay sensitivity both on laboratory and point-of-care platforms. GlobalData expects these advancements to have an impact on other diagnostic tests such as creatine kinase-MB isoenzyme ... \| read more...	$4,450.00
Elan Corporation, plc – Product Pipeline Review – 2013 4/30/2013 \| published by: Global Markets Direct ... focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Markets Direct’s proprietary databases, ... \| read more...	$1,500.00
Celgene Corporation – Product Pipeline Review – 2013 4/30/2013 \| published by: Global Markets Direct ... includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Celgene Corporation’s corporate ... \| read more...	$1,500.00
Nektar Therapeutics – Product Pipeline Review – 2013 4/30/2013 \| published by: Global Markets Direct ... includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Nektar Therapeutics’s corporate ... \| read more...	$1,500.00
MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - Current and Future Players 4/30/2013 \| published by: GlobalData ... of the major killers in the mature markets. Though the incidence of ACS is either in decline or steady across the US and European countries, millions of ACS and suspected ACS patients still visit emergency ... \| read more...	$3,500.00
Antisense Therapeutics Limited – Product Pipeline Review – 2013 4/30/2013 \| published by: Global Markets Direct ... focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Markets Direct’s proprietary databases, ... \| read more...	$1,500.00
ImmunoGen, Inc - SWOT, Strategy and Corporate Finance Report 4/26/2013 \| published by: MarketLine ... actions, providing a 360° view of the company. Features: Detailed information on ImmunoGen, Inc required for business and competitor intelligence needs A study of the major internal and external factors affecting ImmunoGen, Inc in the ... \| read more...	$175.00
Biotechnology in the US - Industry Risk Rating Report 4/24/2013 \| published by: IBISWorld ... the business operating environment'. The report looks at the operational risk associated with this industry. Three types of risk are recognized in our analysis. These are: risk arising from within the industry itself (structural risk), ... \| read more...	$1,020.00

< prev 1 2 3 4 5 6 7 8 9 10 next >